Failure of Physostigmine in Treatment of Acute Severe Intrathecal Baclofen Intoxication
Authors:
- L SaltuariLSL Saltuari
- H BaumgartnerHBH Baumgartner
- M KoflerMKM Kofler
- E SchmutzhardESE Schmutzhard
- L RusseggerLRL Russegger
- F AichnerFAF Aichner
- F GerstenbrandFGF Gerstenbrand
- 24 May 1990
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 322 (21) , 1533-1534
Abstract
Intrathecal baclofen, supplied by implanted drugdelivery systems, has now been established as an effective treatment for spinal spasticity1 and is currently being explored for its usefulness in treating supraspinal spasticity.2 Overdosage is an inherent risk of this approach, with respiratory depression being of most concern in patients with this condition, as has been pointed out in letters to the Editor (Nov. 16 issue).3 , 4 Intravenous physostigmine has been proposed as an "antidote,"5 , 6 but our experience casts doubt on its value in cases of severe intrathecal baclofen overdose.Keywords
This publication has 6 references indexed in Scilit:
- Neurologic Reactions after a Therapeutic Dose of MefloquineNew England Journal of Medicine, 1989
- Physostigmine in the treatment of intrathecal baclofen overdoseJournal of Neurosurgery, 1989
- INTRATHECAL BACLOFEN FOR INTRACTABLE SPASTICITY DUE TO SEVERE BRAIN INJURYThe Lancet, 1989
- Intrathecal Baclofen for Severe Spinal SpasticityNew England Journal of Medicine, 1989
- Long-term intrathecal baclofen infusion for treatment of spasticityJournal of Neurosurgery, 1987
- REVERSIBLE COMA DUE TO INTRATHECAL BACLOFENThe Lancet, 1986